LISATA THERAPEUTICS, INC. — Director's Dealing 2012

Jul 6, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NeoStem, Inc. (NBS)
CIK: 0000320017
Period of Report: 2012-07-05

Reporting Person: Smith Robin L (Director, Chairman of the Board and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-07-05	Common Stock, $0.001 par value	A	150000	$.52	Acquired	1659533	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-07-05	Stock Option (Right to Buy)	$0.52	A	700000	Acquired	2022-07-04	Common stock, par value $0.001 per share (700000)	Direct

Footnotes

F1: On July 5, 2012, the date of grant ("Grant Date"), the reporting person was granted 150,000 shares of restricted common stock, par value $0.001 per share ('Common Stock") of NeoStem, Inc. (the "Company") pursuant and subject to the Company's 2009 Equity Compensation Plan. The Common Stock was fully vested on the Grant Date.

F2: On the Grant Date, the reporting person was granted an option (the "Option") to purchase 700,000 shares of Common Stock of the Company, pursuant and subject to the terms and conditions of the Company's 2009 Equity Compensation Plan. The per share exercise price was equal to the closing price of a share of Common Stock on the Grant Date and the Option shall have a term of ten years despite termination of employment.